HUE055919T2 - Stabil, vizes bázisú ellenanyag-készítmények - Google Patents
Stabil, vizes bázisú ellenanyag-készítményekInfo
- Publication number
- HUE055919T2 HUE055919T2 HUE14855343A HUE14855343A HUE055919T2 HU E055919 T2 HUE055919 T2 HU E055919T2 HU E14855343 A HUE14855343 A HU E14855343A HU E14855343 A HUE14855343 A HU E14855343A HU E055919 T2 HUE055919 T2 HU E055919T2
- Authority
- HU
- Hungary
- Prior art keywords
- stable aqueous
- antibody preparations
- aqueous antibody
- preparations
- stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895143P | 2013-10-24 | 2013-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE055919T2 true HUE055919T2 (hu) | 2022-01-28 |
Family
ID=52993565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE14855343A HUE055919T2 (hu) | 2013-10-24 | 2014-10-23 | Stabil, vizes bázisú ellenanyag-készítmények |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20150118249A1 (enExample) |
| EP (2) | EP3060229B1 (enExample) |
| JP (3) | JP6483673B2 (enExample) |
| KR (3) | KR102238065B1 (enExample) |
| CN (4) | CN112107538A (enExample) |
| AU (4) | AU2014339984B2 (enExample) |
| BR (1) | BR112016008576B1 (enExample) |
| CA (1) | CA2926089C (enExample) |
| CY (1) | CY1125697T1 (enExample) |
| DK (1) | DK3060229T3 (enExample) |
| ES (1) | ES2893861T3 (enExample) |
| HR (1) | HRP20211371T1 (enExample) |
| HU (1) | HUE055919T2 (enExample) |
| LT (1) | LT3060229T (enExample) |
| MX (2) | MX388893B (enExample) |
| PL (1) | PL3060229T3 (enExample) |
| PT (1) | PT3060229T (enExample) |
| RS (1) | RS62419B1 (enExample) |
| RU (1) | RU2763787C2 (enExample) |
| SG (2) | SG11201603206UA (enExample) |
| SI (1) | SI3060229T1 (enExample) |
| SM (1) | SMT202100580T1 (enExample) |
| WO (1) | WO2015061584A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| CA2870149A1 (en) * | 2012-05-03 | 2013-11-07 | Medimmune, Llc | Method for analyzing sample components |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| LT3060229T (lt) * | 2013-10-24 | 2021-09-27 | Astrazeneca Ab | Stabilios vandeninės antikūno vaistinės formos |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| WO2017046776A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| EP3383435A4 (en) * | 2015-11-30 | 2019-07-10 | Medimmune, LLC | OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS |
| US12065482B2 (en) | 2016-08-10 | 2024-08-20 | Celltrion Inc. | Stable liquid pharmaceutical formulation of anti-influenza virus antibody |
| ES3064802T3 (en) * | 2016-10-21 | 2026-04-29 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| JP7641908B2 (ja) * | 2019-03-29 | 2025-03-07 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用 |
| TW202126688A (zh) | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| CN114786724A (zh) * | 2019-12-16 | 2022-07-22 | 尼普洛株式会社 | 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备 |
| CN111024963A (zh) * | 2019-12-27 | 2020-04-17 | 桂林英美特生物技术研究所 | 一种液体稳定、抗冰冻的免疫比浊法载脂蛋白b单试剂 |
| US20230115267A1 (en) * | 2020-03-13 | 2023-04-13 | Samsung Bioepis Co., Ltd. | Pharmaceutical liquid composition having increased stability |
| CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业（上海）股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
| JP2023553641A (ja) * | 2020-12-17 | 2023-12-25 | アストラゼネカ アクチボラグ | 抗ｉｌ５ｒ抗体製剤 |
| DE212025000115U1 (de) * | 2024-07-30 | 2026-06-18 | Sairopa B.V. | Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2004007520A2 (en) * | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
| BRPI0410658B8 (pt) * | 2003-05-26 | 2021-06-22 | In Baik Woo | seringa descartável |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| DE202006001995U1 (de) * | 2006-02-07 | 2006-06-08 | Sarstedt Ag & Co. | Probengefäß zur Aufnahme von kleinen Flüssigkeitsmengen für Analysen |
| SMP200800064B (it) * | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
| KR101540823B1 (ko) * | 2007-03-30 | 2015-07-30 | 메디뮨 엘엘씨 | 항체 제제 |
| PT3072525T (pt) * | 2007-05-14 | 2018-04-20 | Astrazeneca Ab | Métodos para reduzir os níveis de basófilos |
| WO2009080541A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Antibody formulation |
| PE20110302A1 (es) * | 2008-09-19 | 2011-05-21 | Hoffmann La Roche | Formulacion farmaceutica de un anticuerpo contra p-selectina |
| PE20120359A1 (es) * | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
| US20100278822A1 (en) * | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| AU2012326170B2 (en) * | 2011-10-18 | 2016-12-22 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with metal ions |
| EP2771358A4 (en) * | 2011-10-26 | 2015-08-26 | Bio Rad Laboratories | ELIMINATION OF VIRAL AGENTS IN MIXED MODE CHROMATOGRAPHY |
| AU2012328524B2 (en) * | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| CN104039352A (zh) * | 2011-11-01 | 2014-09-10 | 米迪缪尼有限公司 | 用于降低哮喘急性恶化的频率和严重性的方法 |
| AR090244A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Formulacion de anticuerpo anti-selectina p |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| SMT201900311T1 (it) * | 2013-08-12 | 2019-07-11 | Astrazeneca Ab | Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab |
| CA2918105C (en) | 2013-08-12 | 2023-02-28 | Medimmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| BR112016002462A8 (pt) | 2013-08-12 | 2018-06-12 | Medimmune Llc | Métodos para melhorar os sintomas da asma usando benralizumabe |
| LT3060229T (lt) * | 2013-10-24 | 2021-09-27 | Astrazeneca Ab | Stabilios vandeninės antikūno vaistinės formos |
-
2014
- 2014-10-23 LT LTEPPCT/US2014/061997T patent/LT3060229T/lt unknown
- 2014-10-23 DK DK14855343.1T patent/DK3060229T3/da active
- 2014-10-23 EP EP14855343.1A patent/EP3060229B1/en active Active
- 2014-10-23 KR KR1020207012828A patent/KR102238065B1/ko active Active
- 2014-10-23 AU AU2014339984A patent/AU2014339984B2/en active Active
- 2014-10-23 KR KR1020167012565A patent/KR102109053B1/ko active Active
- 2014-10-23 JP JP2016525876A patent/JP6483673B2/ja active Active
- 2014-10-23 ES ES14855343T patent/ES2893861T3/es active Active
- 2014-10-23 CN CN202010809794.1A patent/CN112107538A/zh active Pending
- 2014-10-23 EP EP20207556.0A patent/EP3892288A1/en active Pending
- 2014-10-23 MX MX2016004605A patent/MX388893B/es unknown
- 2014-10-23 KR KR1020217009731A patent/KR20210041101A/ko not_active Ceased
- 2014-10-23 CA CA2926089A patent/CA2926089C/en active Active
- 2014-10-23 RS RS20211238A patent/RS62419B1/sr unknown
- 2014-10-23 SG SG11201603206UA patent/SG11201603206UA/en unknown
- 2014-10-23 CN CN202110799711.XA patent/CN113350278B/zh active Active
- 2014-10-23 HU HUE14855343A patent/HUE055919T2/hu unknown
- 2014-10-23 SI SI201431876T patent/SI3060229T1/sl unknown
- 2014-10-23 SM SM20210580T patent/SMT202100580T1/it unknown
- 2014-10-23 SG SG10201803178UA patent/SG10201803178UA/en unknown
- 2014-10-23 PL PL14855343T patent/PL3060229T3/pl unknown
- 2014-10-23 HR HRP20211371TT patent/HRP20211371T1/hr unknown
- 2014-10-23 BR BR112016008576-0A patent/BR112016008576B1/pt active IP Right Grant
- 2014-10-23 CN CN201480055263.0A patent/CN105611938B/zh active Active
- 2014-10-23 WO PCT/US2014/061997 patent/WO2015061584A1/en not_active Ceased
- 2014-10-23 CN CN202411964617.5A patent/CN119971024A/zh active Pending
- 2014-10-23 RU RU2016119755A patent/RU2763787C2/ru active
- 2014-10-23 US US14/521,870 patent/US20150118249A1/en not_active Abandoned
- 2014-10-23 PT PT14855343T patent/PT3060229T/pt unknown
-
2016
- 2016-04-11 MX MX2021015825A patent/MX2021015825A/es unknown
-
2019
- 2019-02-14 JP JP2019024364A patent/JP6896781B2/ja active Active
- 2019-03-11 US US16/298,474 patent/US12582716B2/en active Active
-
2020
- 2020-03-25 US US16/829,659 patent/US20200297855A1/en not_active Abandoned
- 2020-07-09 AU AU2020204608A patent/AU2020204608A1/en not_active Abandoned
-
2021
- 2021-06-09 JP JP2021096239A patent/JP2021152034A/ja active Pending
- 2021-10-19 CY CY20211100902T patent/CY1125697T1/el unknown
-
2022
- 2022-12-23 AU AU2022291595A patent/AU2022291595B2/en active Active
-
2025
- 2025-02-04 US US19/045,166 patent/US20250170245A1/en active Pending
- 2025-09-12 AU AU2025230794A patent/AU2025230794A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3060229T3 (pl) | Stabilne, wodne formulacje przeciwciała | |
| CL2016000680A1 (es) | Formulaciones de anticuerpos anti-pdl1. | |
| IL244189A0 (en) | Certain chemical entities, compositions, and methods | |
| HUE051862T2 (hu) | Stabil, IFNAR1-elleni készítmény | |
| IL244879B (en) | Aqueous herbicidal concentrates | |
| FR3006466B3 (fr) | . | |
| BR302014001381S1 (pt) | Configuração aplicada em bolsa. | |
| DK2951203T3 (da) | Heterodimere proteiner | |
| CL2016000077A1 (es) | Azinas herbicidas. | |
| HUE060756T2 (hu) | Fungicid hatású készítmények | |
| DK3041857T3 (da) | Protein a-kromatografi | |
| HUE060909T2 (hu) | Mûtrágya készítmények | |
| DK2975030T3 (da) | Dihydropyridazin-3,5-dion-derivat | |
| DK3055664T3 (da) | Faldlodsdeflektometer. | |
| IL242795B (en) | Compositions, methods, and devices for dialysis | |
| CL2016000126A1 (es) | Compuestos plaguicidas. | |
| HRP20181663T1 (hr) | Priprema (s,s)-sekoizolaricirezinol diglukozida i (r,r)-sekoizolaricirezinol diglukozida | |
| HUE058086T2 (hu) | Lassú hatóanyagleadású szilárd készítmények | |
| FR3001302B1 (fr) | . | |
| IL241772B (en) | Pyrazole derivatives, compositions comprising same and uses thereof | |
| ES1086107Y (es) | Contenedor armable. | |
| DK3089990T3 (da) | Forbedret proteinekspression | |
| HRP20171888T1 (hr) | Farmaceutski pripravci | |
| FR3001303B1 (fr) | . | |
| DK3089991T3 (da) | Forbedret proteinekspression |